Source: Investing.com ↗

Tyra Biosciences stock tumbles 30% on phase 2 trial results

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

USDC/USDT

$1.0000

-0.02%

BTC/USDT

$85,723.22

-0.65%

ETH/USDT

$2,729.04

-0.87%

ZEC/USDT

$1,613.26

+7.81%

XRP/USDT

$1.59

+2.98%